TY - JOUR T1 - Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 2025 LP - 2030 DO - 10.1136/annrheumdis-2017-211623 VL - 76 IS - 12 AU - Louise K Mercer AU - Anne C Regierer AU - Xavier Mariette AU - William G Dixon AU - Eva Baecklund AU - Karin Hellgren AU - Lene Dreyer AU - Merete Lund Hetland AU - René Cordtz AU - Kimme Hyrich AU - Anja Strangfeld AU - Angela Zink AU - Helena Canhao AU - M Victoria Hernandez AU - Florence Tubach AU - Jacques-Eric Gottenberg AU - Jacques Morel AU - Jakub Zavada AU - Florenzo Iannone AU - Johan Askling AU - Joachim Listing Y1 - 2017/12/01 UR - http://ard.bmj.com/content/76/12/2025.abstract N2 - Background Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes.Methods Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD.Results Among 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population.Conclusion This large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients. ER -